Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bronchoalveolar Cell Lung Cancer Clear all

Conditions: Lung Cancer
Interventions: canfosfamide hydrochloride; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 3
States / cities: Morristown, New Jersey • New Brunswick, New Jersey • Cleveland, Ohio

Conditions: Lung Cancer
Interventions: accelerated conformational radiotherapy; Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 20
States / cities: Fort Lauderdale, Florida • Hollywood, Florida • Jupiter, Florida + 15 more

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Interventions: paclitaxel, carboplatin, therapeutic conventional surgery; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer
Interventions: cisplatin, docetaxel, gemcitabine hydrochloride, pemetrexed disodium, vinorelbine tartrate, standard follow-up care; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 93
States / cities: Anniston, Alabama • Birmingham, Alabama • Burbank, California + 66 more

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: cetuximab, paclitaxel, bevacizumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: paclitaxel, carboplatin, gefitinib, radiation therapy, laboratory biomarker analysis; Drug · Radiation · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer, Metastatic Cancer
Interventions: Erlotinib plus Romidepsin (8 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis, (Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis; Combination Product
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib; Radiation · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 232
States / cities: Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more

Conditions: Lung Cancer
Interventions: filgrastim, pegfilgrastim, cisplatin, docetaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 76
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Concord, California + 64 more

Conditions: Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma
Interventions: Akt Inhibitor MK2206, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 4 more

Conditions: Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation Therapy, Carboplatin, Metformin, Paclitaxel; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 219
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Auburn, California + 176 more

Conditions: Lung Cancer
Interventions: positron emission tomography, radionuclide imaging, fludeoxyglucose F 18; Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Clearwater, Florida + 17 more

Conditions: Lung Cancer
Interventions: topotecan hydrochloride, vinorelbine tartrate; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 120 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Lung Cancer, Pulmonary Complications
Interventions: educational intervention, supervised exercise program; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 60
States / cities: Fort Collins, Colorado • Decatur, Illinois • Maywood, Illinois + 32 more

Conditions: Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium; Drug · Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 5
States / cities: Sacramento, California • Worcester, Massachusetts • The Bronx, New York

Conditions: Lung Cancer
Interventions: cetuximab, carboplatin, paclitaxel, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Lung Cancer
Interventions: adjuvant therapy, diagnostic thoracoscopy, therapeutic thoracoscopy, video-assisted surgery, radiation therapy; Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2005
U.S. locations: 13
States / cities: Denver, Colorado • Des Moines, Iowa • Boston, Massachusetts + 8 more

Conditions: Lung Cancer, Bilateral Cancer, Lung Transplant
Interventions: Double Lung Transplantation; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer
Interventions: stereotactic body radiation therapy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 2
States / cities: Rochester, New York • Houston, Texas

Conditions: Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
Interventions: darbepoetin alfa, pegfilgrastim, cisplatin, docetaxel, BNP7787; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 64
States / cities: Mountain View, California • Lewes, Delaware • Newark, Delaware + 42 more

Conditions: Lung Cancer, Non-Small Cell
Interventions: GW572016 (lapatinib); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 23
States / cities: Jasper, Alabama • Greenbrae, California • La Jolla, California + 20 more

Conditions: Lung Cancer, Metastatic Cancer
Interventions: isolated perfusion, paclitaxel, hyperthermia treatment; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: clinical observation, radiation therapy; Other · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 168
States / cities: Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 103 more

Search by objective public record fields.

TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction

Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer

Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

Positron Emission Tomography for Detecting Non-small Cell Lung Cancer

Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer

S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer

Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer

Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function

DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies

Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer